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Abstract: The urotensin II receptor, bound by the ligand urotensin II, generates second 
  messengers, ie, inositol triphosphate and diacylglycerol, which stimulate the subsequent 
release of calcium (Ca2+) in vascular smooth muscle cells. Ca2+ influx leads to the activation 
of Ca2+-dependent kinases (CaMK) via calmodulin binding, resulting in cellular proliferation. 
We hypothesize that urotensin II signaling in pulmonary arterial vascular smooth muscle cells 
(Pac1) and primary aortic vascular smooth muscle cells (PAVSMC) results in phosphorylation of 
Ca2+/calmodulin-dependent kinases leading to cellular proliferation. Exposure of Pac1 cultures 
to urotensin II increased intracellular Ca2+, subsequently activating Ca2+/calmodulin-dependent 
kinase kinase (CaMKK), and Ca2+/calmodulin-dependent kinase Type I (CaMKI), extracellular 
signal-regulated kinase (ERK 1/2), and protein kinase D. Treatment of Pac1 and PAVSMC 
with urotensin II increased proliferation as measured by 3H-thymidine uptake. The urotensin 
II-induced increase in 3H-thymidine incorporation was inhibited by a CaMKK inhibitor. Taken 
together, our results demonstrate that urotensin II stimulation of smooth muscle cells leads to 
a Ca2+/calmodulin-dependent kinase-mediated increase in cellular proliferation.
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Introduction
Hypertrophy, inflammation, and proliferation of vascular cells are major contributors 
to diseases such as atherosclerosis, arteriosclerosis, and hypertension.1 The combined 
effects of these major contributors are increases in cell size, migration of immune 
cells, and abnormal cell growth in affected regions of the vessel.2 Changes in vessel 
structure due to vascular remodeling result in narrowing of the vessel wall and arterial 
stiffness.2 Contraction and relaxation of vascular smooth muscle cells are regulated 
by biologically active mediators which are synthesized and secreted to modulate 
vascular tone.1 Many of these same mediators also play a pathologic role, such as 
urotensin II, which can induce abnormal cellular proliferation during disease-related 
vascular remodeling.1
Urotensin II is similar to somatostatin in both structure and function. Urotensin II 
is an undecapeptide cleaved from a precursor molecule that stimulates potent vasocon-
striction and vascular smooth muscle cell proliferation.3,4 Under nonpathologic condi-
tions, urotensin II influences vascular smooth muscle contraction.5 However, under 
pathologic conditions, urotensin II promotes cellular migration, and modulates large 
blood vessels, as shown in studies conducted in human aortic smooth muscle cells.6
Urotensin II is recognized by the orphan G-protein coupled GPR-14, now identi-
fied as the urotensin II receptor, resulting in generation of the second messengers, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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inositol triphosphate and diacylglycerol.7,8 These second 
messengers trigger the release of Ca2+ from the sarcoplasmic 
reticulum.9 The urotensin II receptor is expressed in many 
tissues, including vascular smooth muscle, although the 
precise mechanisms activated downstream of the urotensin 
II receptor in vascular smooth muscle cells are largely 
unknown.10 Studies of other Gq-coupled receptors have 
shown that stimulation induces intracellular Ca2+ influx and 
binding of Ca2+ to calmodulin.11,12 Activated calmodulin 
subsequently binds to and stimulates calmodulin-dependent 
kinases (CaMK), such as Ca2+/calmodulin-dependent kinase 
kinase (CaMKK).13 Activation of CaMK members can lead 
to Ca2+-dependent activation of other protein kinases, such 
as extracellular signal-regulated kinase (ERK) and protein 
kinase D (PKD).14–16
ERK phosphorylation is required for proliferation of 
various cell types and cell lines.17,18 Vascular remodeling, 
hypertrophy, and proliferative responses are believed to 
be the result of urotensin II receptor overstimulation.19,20 
Studies in thoracic aortic cells demonstrated that urotensin 
II receptor signaling stimulates the phosphorylation of 
ERK.5,21 In addition to ERK activation, intracellular Ca2+ 
influx can also modulate the activity of PKD.14 Vasoac-
tive agents, such as endothelin-1, that bind Gq-coupled 
receptors, have been demonstrated to mediating PKD 
phosphorylation in various cell types.22 Here, we show 
that urotensin II induces intracellular Ca2+ release which 
stimulates CaMKI phosphorylation in Pac1. Moreover, we 
demonstrate that urotensin II receptor stimulation leads to 
CaMK-dependent phosphorylation of ERK and PKD. We 
go on to reveal that the acute application of urotensin II 
results in cellular proliferation, which can be blocked by 
inhibition of CaMKK. Consistent with our hypothesis, we 
have found that urotensin II-induced CaMKI, ERK, and 
PKD phosphorylation are also blocked by inhibition of 
CaMKK in vascular smooth muscle cells. These observa-
tions potentially indicate that urotensin II-induced signaling 
triggers proliferation and may contribute to hypertrophic 
pathologic conditions.
Materials and methods
Cell culture
Rat pulmonary arterial smooth muscle cells (Pac1) were 
cultured according to the method described by Rothman A 
et al.11 In brief, rat Pac1 were cultured in medium 199 (Invit-
rogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum with gentamicin (Fisher Scientific, Pittsburgh, PA). 
The cells were carried only through passages 3–15.
Primary aortic smooth muscle cells
Rat aortas were isolated from three-month-old Sprague-
Dawley rats according to an established protocol.23 The aortas 
were incubated for five minutes in 10% fetal bovine serum 
and 199 medium, then incubated at 37°C for 30 minutes in 
Hanks Balanced Salt Solution (Invitrogen-GIBCO, Carlsbad, 
CA) with 70 U/mL of collagenase (Millipore-Worthington 
Biochemical Company, Billerica, MA). Adventitias were 
stripped from the aortic tissue with watchmaker forceps and 
discarded. Aortas were digested in Hanks Balanced Salt Solu-
tion with collagenase 70 U/mL and elastase 40 U/mL (Sigma 
Aldrich, St Louis, MO). Aortas were gently agitated at 37°C 
for 90 minutes. The aortic solution was passed through 
a strainer with a 70 µm pore size, and centrifuged at 900 
rpm for five minutes. Cellular suspensions were dispersed 
by pipetting the suspensions up and down. Cells were then 
plated in six-well plates containing 10% fetal bovine serum 
in 199 medium.
Calcium imaging
Pac1 (1 × 105 cells/mL) were grown on coverslips at 
70%–80% confluency, and then bathed in Hanks Balanced 
Salt Solution (containing NaCl 0.137 M, KCl 5.4 mM, 
Na2PO4 0.25 mM, KH2PO4 0.44 mM, MgSO4 1.0 mM, 
NaHCO3 4.2 mM) with and without Ca2+ for measuring 
intracellular Ca2+. Detection of intracellular Ca2+ was quanti-
fied using a ratiometric technique recognized by Fura-2-AM 
(Invitrogen) involving excitation at 340 nm and 380 nm with 
emission at 510 nm according to Prasanne et al.24 A Nikon 
Diaphot microscope using Metafluor software (Universal 
Imaging, West Chester, PA) was used to measure intracellular 
Ca2+. Concentration (nM) of intracellular Ca2+ was calculated 
using the Grynkeiwicz equation. Ethylenediamine tetraacetic 
acid 0.5 µM, a membrane-impermeable chemical chelating 
agent that binds Ca2+, was used to reverse the elevated levels 
of Ca2+. BAPTA-AM (1, 2-bis(2-aminophenoxy)- ethane-
N,N,N’, N’-tetra-acetic acid) 10 µM (Invitrogen) was also 
used as a Ca2+ chemical chelating agent. BAPTA-AM, a 
membrane-permeable compound, also reverses the elevated 
levels of intracellular Ca2+.
Immunostaining
Pac1 and PAVSMC were cultured (1 × 105 cells/mL) on 
glass coverslips and washed twice with phosphate-buffered 
solution and fixed for 15 minutes with 4% paraformal-
dehyde at room temperature. Cells were blocked for one 
hour in blocking solution (3.0% bovine serum albumin 
in phosphate-buffered solution), and then incubated for Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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one hour in primary antibody smooth muscle cell-specific 
antimyosin IgG (Biomedical Technologies Incorporated, 
Stoughton, MA) diluted 1:200 or anti-GPR14R (antibody 
for the urotensin II receptor, Alpha Diagnostic International 
Inc., Woodlake Center, TX) antibody 1:200 with blocking 
solution. The secondary fluorescent labeling was incubated 
with cells using 1:500 Alexa 488 goat/antirabbit (Molecular 
Probes- Invitrogen, Eugene, OR) in blocking solution. The 
cells were washed three times with phosphate-buffered 
solution. Coverslips were mounted on slides with Pro-Long 
Gold Anti-Fade and DAPI (Invitrogen). A DP70 Olympus 
digital camera and AX70 fluorescent microscope was used 
to visualize stained cells (40 × objective).
3H-thymidine incorporation assay
Pac1 and PAVSMC were seeded (8 × 104 cells/mL) in RPMI 
(Invitrogen) medium containing 10% fetal bovine serum. 
After 70% confluency, cells were washed with phosphate-
buffered solution and serum starved in serum-free media 
to induce G1 arrest. Cells were serum-starved for 24 and 
48 hours and were incubated in serum-free RPMI media or 
isotonic artificial CSF (ACSF, 142 mM NaCl, 5 mM KCl, 
10 mM glucose, 1.3 mM Mg2+ 10 mM HEPES, and in the 
presence or absence of 3.1 mM Ca2+ containing 1 µCi/mL 
of 3H-thymidine, specific activity 48.0 Ci/mmol (GE-Health-
care-Amersham Pharmacia, Piscataway, NJ) for four hours 
in the CO2 incubator at 37°C in the presence and absence of 
urotensin II 100 nM (Sigma Aldrich) and STO609 250 nM 
(Sigma Aldrich). After the four-hour incubation period, cells 
were washed with phosphate-buffered solution. Cells were 
precipitated with 15% trichloroacetic acid and incubated 
overnight at 4°C. Cells were then lysed with 1 Normal NaOH 
and were incubated for 30 minutes at room temperature. Cell 
lysates were transferred to tubes containing scintillation fluid 
for analysis using a Beckman 1539 scintillation counter. Pro-
liferation was measured by incorporation of 3H-thymidine.
Western blot analysis
Pac1 were seeded at a density of 4 × 104 cells/mL and cul-
tured until cells were 80% confluent in 100 mm3 dishes. 
The day prior to treatment, the cells were serum-reduced 
in 0.1% fetal bovine serum and 199 medium with gen-
tamicin   (Invitrogen) or 0.1% fetal bovine serum in ACSF. 
Twenty-four hours after serum reduction, cells were treated 
with 100 nM rat urotensin II (Sigma Aldrich), and 250 nM 
STO609, a synthetic 7-oxo-7H-benzimidazo [2,1-a]benz[de]
isoquinoline-3-carboxylic acid-acetic acid peptide (Sigma 
Aldrich). All treatment conditions were carefully selected 
based on preliminary dose- and time-dependent studies. 
Experiments with the use of inhibitors were conducted 
under optimal conditions, and the concentrations were based 
on previous studies as referenced earlier. Inhibitors were 
incubated 30 minutes prior to urotensin II treatments. Dose-
  response and time-course investigations were conducted with 
urotensin II treatment. Cells were lysed using RIPA buffer 
(50 mM TrisHCl, 150 mM NaCl, 2 mM ethylenediamine 
tetraacetic acid, 1% NP-40, and 0.1% sodium dodecyl sulfate 
pH 7.4) and a protease inhibitor cocktail (Sigma Aldrich) 
containing phosphate inhibitors. Protein concentration was 
measured by the bicinchoninic acid method. Equal amounts 
of protein (20–30 µg) were loaded and electrophoresed 
in 10% sodium dodecyl sulfate-acrylamide gel. Proteins 
were transferred to PVDF membrane (Millipore, Billerica, 
MA). The membrane was incubated with respective phos-
phospecific primary antibodies at 4°C overnight and with 
corresponding horseradish peroxidase-conjugated secondary 
antibody at room temperature for one hour. After washing 
with 1 × phosphate-buffered solution three times at room 
temperature, the phosphorylation state of the proteins were 
detected by chemiluminescence (GE Healthcare Amersham). 
Phosphospecific antibodies used for the Western blots were 
p-ERK1/2 (Cell Signaling-9106S), p-PKD (Cell Signaling, 
Boston, MA) and pCaMKI (threonine 178, T Soderling Vol-
lum Institute, Oregon Health Science University, Portland, 
OR). Loading control was determined by stripping the blot 
and reprobing with anti-beta actin antibody (Santa Cruz 
Biotech, Santa Cruz, CA). Expression of the urotensin II 
receptor was measured using anti-GPR14R (antibody for 
the urotensin II, Alpha Diagnostic International Inc., San 
Antonios, TX) antibody.
Adenoviral infection
Pac1 were seeded into six-well plates. Cells were grown 
in 199 medium containing 10% serum with penicillin and 
streptomycin. Cells were allowed to reach near confluency 
and were infected with the adenovirus Ad- urotensin II and 
Ad-GO-GFP. The adenovirus-containing (Ad-urotensin II-
GFP) and the control adenovirus (Ad-GO-GFP) were both 
obtained from Walter Thomas (Baker Heart Research Insti-
tute, Melbourne, Australia).25 Plaque forming units (PFU) 
in HEK293 cells were measured to determine the viral titer, 
which was approximately 1.5 × 107 PFU/mL. The efficiency 
of infection for viral load was determined by observation of 
GFP fluorescence under the microscope. Virus-containing 
media was washed from the cells, and 10% serum-containing 
media was incubated for 18 hours for expression of virus.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Statistical analysis
Western blot densitometry values were normalized and 
evaluated relative to control. Ca2+ imaging data were pre-
sented relative to control in terms of percentage change. 
Densitometry, Ca2+, and proliferation data were subjected to 
one-way analysis of variance (ANOVA, GraphPad-Prism, 
San Diego, CA) and the Newman-Keuls multiple range test 
was used for pairwise comparisons of the means. Statistical 
significance was indicated by P # 0.05.
Results
Urotensin II receptor is expressed  
in Pac1 and PAVSMC
To investigate urotensin II-induced signaling, we used both 
Pac1 and PAVSMC to verify the expression of the urotensin II 
receptor. Pac1 are rapidly dividing cells,11 and therefore may 
not accurately represent the characteristics observed in normal 
vascular smooth muscle cells. Thus, we incorporated the 
two cell types to identify the urotensin II receptor signaling 
mechanisms. Previous studies have identified urotensin II 
receptor expression in PAVSMC, but urotensin II receptor 
expression in Pac1 lines have not been examined.10 Western 
blot analysis confirms that Pac1 have higher levels of the 
urotensin II receptor compared with PAVSMC (Figure 1A). 
Immunocytostaining of both cell types with anti-urotensin II 
receptor antibody indicated the presence of the urotensin II 
receptor in both Pac1 and PAVSMC (Figure 1B).
Urotensin II induces mobilization  
of Ca2+ in Pac1 and PAVSMC
It is well established that binding of urotensin II to the uro-
tensin II receptor leads to mobilization of intracellular Ca2+.26 
We measured intracellular Ca2+ transients in urotensin II-
treated Pac1 and PAVSMC using Fura-2-AM dye and digital 
imaging microfluorometry. Figures 2A and 2B demonstrate 
that urotensin II increases Ca2+ to 800 nM over 30 seconds 
in Pac1 (Figure 2A) and 600 nM in PAVSMC (Figure 2B). 
Pac1 and PAVSMC (Figure 2C) are representative images 
before and after urotensin II treatment. The Fura-2-AM scale, 
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Figure 1 Urotensin II is expressed in Pac1 and PAVSMC. A) A representative 
immunoblot using anti-GPR14 (antibody to urotensin II) demonstrates that urotensin II 
is expressed in both Pac1 and PAVSMC. Densitometry analysis was conducted on 
Western blots (n = 3, *P # 0.05). B) Merged image urotensin II immunocytochemistry 
in Pac1 (image 20 × objective) and PAVSMC (image 40 × objective) cells is highlighted 
by the green stain using anti-GPR14 antibody (antibody to urotensin II) and the 
nuclei staining is identified with DAPI, which is shown in blue.
Abbreviations: Pac1, pulmonary arterial vascular smooth muscle cells; PAVSMC, 
primary aortic vascular smooth muscle cells.
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Figure 2 Urotensin II induces elevated levels of intracellular Ca2+ in Pac1 and 
PAVSMC. Modulation of intracellular Ca2+ in response to urotensin II treatment in 
Pac1 (A) and PAVSMC (B) preloaded with Fura-2 and treated with urotensin II. Cells 
were captured at the 340/380 fluorescence ratio of Fura-2 and cells were monitored 
to detect changes in Ca2+. Urotensin II concentrations were chosen according to 
our previous dose response studies. Data are from an average of Ca2+ response 
in a population of Pac1(A) and PAVSMC (B) stimulated with urotensin II (n = 14), 
and a representation of three independent experiments of urotensin II treatment 
in Pac1 and PAVSMC were graphically plotted. Urotensin II-induced mobilization of 
Ca2+ response was plotted as Ca2+ concentration versus time. D) A representative 
scale demonstrating the correlation between color and Ca2+ levels. High levels of 
Ca2+ are shown with bright colors (yellow/red/orange) and low levels correspond to 
the dark colors (violet/blue/green). C) Fluorescent images of Pac1 and PAVSMC C 
cells were captured with preloaded Fura-2 AM and urotensin II treatment. Images 
depict (C-top) control and (C-bottom). E) Pac1 cells were treated with urotensin 
II and Hanks Balanced Salt Solution ± Ca2+. These treatment groups were compared 
to determine if intracellular Ca2+ is the predominant source. Pac 1 exposed to 
membrane-impermeable ethylenediamine tetraacetic acid and membrane-permeable 
BAPTA-AM were used to reverse the elevated levels of Ca2+. Experiments were 
conducted in three separate experiments (n = 14, *P # 0.05).
Abbreviations: Pac1, pulmonary arterial vascular smooth muscle cells; PAVSMC, 
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as shown in Figure 2D, illustrates the level of intracellular 
Ca2+, demonstrating that urotensin II induces an increase in 
Ca2+. In Figure 2E we show that urotensin II-induced Ca2+ 
release does not depend on extracellular Ca2+. The increase 
in cytoplasmic Ca2+ in response to urotensin II is the same 
for cells cultured in Hanks Balanced Salt Solution media 
with or without Ca2+. Ethylenediamine tetraacetic acid 
(membrane-impermeable) and BAPTA-AM (membrane-
permeable) served as our controls in Figure 2E. Taken as a 
whole, the results in Figure 2 suggest that 100 nM urotensin 
II causes a release of Ca2+ from internal stores in Pac1 and 
PAVSMC. Urotensin II induces phosphorylation of CaMKI, 
ERK, and PKD in Pac1. Western blot analysis was used 
to assess phosphorylation of CaMKI, PKD, and ERK in 
response to urotensin II (Figures 3A–3F) in Pac1. There 
was a dose-dependent (Figures 3A–C) and time-  dependent 
 ( Figures 3D–F) increase in CaMKI   phosphorylation 
 ( Figures 3A and 3D). PKD phosphorylation (Figures 3B 
and 3E), and ERK phosphorylation (Figures 3C and 3F) in 
Pac1 treated with urotensin II. Using 100 nM urotensin II, 
CaMKI phosphorylation was maximal at 10 minutes, and 
preceded PKD phosphorylation, which peaked at 15 min-
utes. Phosphorylation of ERK occurred later and was still 
increasing at 60 minutes.
Urotensin II-induced phosphorylation of CaMKI, 
PKD, and ERK reduced in presence of CaMKK 
inhibitor in Pac1
To test if CaMKK is an integral target affecting the activation 
of several downstream effectors in the urotensin II signaling 
cascade, we used the CaMKK inhibitor prior to the addition 
of 100 nM urotensin II for 10 minutes, and measured CaMKI 
phosphorylation via Western blot analysis (Figure 4A). 
Our results in Figure 4A revealed that STO609 blocked the 
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Figure 3 Urotensin II induces phosphorylation of CaMKI, PKD, and ERK in Pac1. Western blot analysis of the time course of CaMKI, PKD, and ERK phosphorylation (A, B, 
and C) and dose response of urotensin II-stimulated phosphorylation CaMKI, PKD, and ERK (D, E, and F) in Pac1 cells. Densitometry analysis was conducted on Western 
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urotensin II-induced phosphorylation of CaMKI. We also 
pretreated Pac1 with 250 nM STO609 for 30 minutes, fol-
lowed by a treatment of 100 nM urotensin II for 15 minutes 
to measure PKD phosphorylation (Figure 4B). Our findings 
demonstrated a reduction in urotensin II-stimulated PKD 
phosphorylation in the presence of STO609 (Figure 4B). We 
then used 250 nM STO609 for a 30-minute pretreatment, fol-
lowed by a treatment of 100 nM urotensin II for 30 minutes. 
Under these treatment conditions, STO609 reduced urotensin 
II-induced ERK phosphorylation in Pac1 (Figure 4C). By and 
large, the inhibition of CaMKK reduces urotensin II-induced 
phosphorylation of CaMKI, PKD, and ERK (Figure 4). 
Therefore, our results with STO609 establish CaMKK’s 
involvement in urotensin II receptor signaling (Figure 4).
Characterization of primary cell cultures
Urotensin II-induced signaling mechanisms are poorly under-
stood in vascular smooth muscle cells, therefore we looked 
at urotensin II receptor signaling in both a cell line and a 
primary culture. We verified isolation of primary rat aortas by 
immunostaining the cells with a smooth muscle cell-specific 
antibody-antimyosin primary antibody for smooth muscle 
cells. As shown in Figure 5A, more than 70% of PAVSMC 
are smooth muscle cell-positive. Western blot analysis was 
used to determine if urotensin II treatment of PAVSMC 
induces ERK phosphorylation. Our results demonstrate that 
PAVSMC exposed to 100 nM urotensin II induces phospho-
rylation of ERK maximally after 15 minutes (Figure 5B). 
Furthermore, 30 minutes of pretreatment with 250 nM 
STO609 blocked urotensin II-induced ERK phosphorylation 
in PAVSMC (Figure 5C). Therefore, our results demon-
strate that   urotensin II induces the phosphorylation of ERK 
in PAVSMC, and CaMKK exposure to PAVSMC blocks 
  urotensin II-induced phosphorylation of ERK (Figure 5).
Urotensin II stimulates proliferation  
of Pac1 and PAVSMC
Studies have linked urotensin II-induced ERK phosphorylation 
with cellular proliferation in thoracic aortic cells.21 Therefore, 
we tested whether urotensin II induces cellular proliferation 
in Pac1 and PAVSMC. We measured 3H-  thymidine uptake 
as a proliferative assay in Pac1 (Figure 6A) and PAVSMC 
(Figure 6B). Cellular proliferation was measured by counting 
numbers of Pac1, and we found that the cell number is greater 
with urotensin II treatment (Figure 6C). Representative images 
of urotensin II-treated Pac1 were taken to show differences 
in cell numbers with urotensin II treatment (Figure 6D). 
Urotensin II induced proliferation of both cell types in a 
dose-dependent manner (Figure 6).
CaMKK inhibitor blocks urotensin II-induced cellular 
proliferation in Pac1 and PAVSMC
Pretreatment with STO609 to inhibit CaMKK blocks uro-
tensin II-induced proliferation of PAVSMC (Figure 7A and 
B) and Pac1 (Figure 7C). Representative images were taken 
(Figure 7E), and cellular proliferation was measured by 
counting cell numbers to show that STO609 blocks urotensin 
II-induced proliferation in Pac1 (Figure 7D).
Extracellular Ca2+ does not alter urotensin II-induced 
phosphorylation of CaMKI and cellular proliferation
To determine if 100 nM urotensin II in the presence of 
extracellular Ca2+ alters CaMKI phosphorylation, the 
  urotensin II-induced phosphorylation status of CaMKI was 
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of A. CaMKI, B. PKD, and C. ERK inhibited by CaMKK. Densitometry analysis was conducted on Western blots (n = 4, *P # 0.05). 
Abbreviations: Pac1, pulmonary arterial vascular smooth muscle cells; PKD, protein kinase D; CaMKI, Ca2+/calmodulin-dependent kinase Type I; ERK, extracellular signal-
regulated kinase; C, control; UII, urotensin II; U/S, urotensin II ± STO609.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
729
Urotensin II-induced signaling in smooth muscle
A
B
C
Beta actin
PAVSMC cells
10%
serum U S U/S
0 - UII (mini)
D
e
n
s
i
t
o
m
e
t
r
y
 
u
n
i
t
s
(
n
o
r
m
a
l
i
z
e
d
 
c
o
n
t
r
o
l
)
D
e
n
s
i
t
o
m
e
t
r
y
 
u
n
i
t
s
(
n
o
r
m
a
l
i
z
e
d
 
t
o
 
s
e
r
u
m
 
f
r
e
e
 
m
e
d
i
a
)
*
* 2.5
2.0
1.5
1.0
0.5
0.0
2.0
2.5
1.5
1.0
0.5
0.0
pERK
42–44 kDa
01 5 UII (min)
Beta actin
pERK
42–44 kDa
60
15 60
SF
10%
serum
US U/S SF
#
*
#
*
Figure 5 Characterization of PAVSMC. A) PAVSMC were immunostained with antimyosin smooth muscle cell-specific antibody to identify if cultured cells are composed 
of vascular smooth muscle cells. Merged image of cultured PAVSMC depicts positive antimyosin smooth muscle cell staining (left image). Antimyosin smooth muscle cell 
antibody is highlighted by the green stain (top image), and the nuclei staining is identified with DAPI, which is shown in blue (bottom image). B) A representative immunoblot 
demonstrates that urotensin II induces ERK phosphorylation in a time-dependent manner. Densitometry analysis was conducted on Western blots (n = 3, *P # 0.05.   
C) and D) A representative Western blot demonstrating that CaMKK blocks urotensin II receptor-induced phosphorylation of ERK (10% serum and 10% fetal bovine serum 
in media (n = 2, *P # 0.05, #P # 0.05). 
Abbreviations: PAVSMC, primary aortic vascular smooth muscle cells; ERK, extracellular signal-regulated kinase; C, control; UII, urotensin II; U/S, urotensin II ± STO609; 
SF, reduced serum media.
measured in 0.1% fetal bovine serum in ACSF media in the 
presence and absence of Ca2+ via Western blot analysis (Fig-
ure 8A and 8B). The results indicated no statistical difference 
between treatment groups (ACSF + urotensin II) and (ACSF 
+ urotensin II + Ca2+, n = 3, Figure 8B). To address the role 
of extracellular Ca2+ and 100 nM urotensin II-induced cellular 
proliferation, we treated cells for 24 hours with reduced serum 
ACSF in the presence and absence of Ca2+ and measured 
cellular proliferation via 3H-thymidine incorporation assay 
(Figure 8C). Results in Figure 8C demonstrate that urotensin 
II treatment in ACSF media, in the presence or absence of 
Ca2+, did not alter the levels of cellular proliferation.
Urotensin II overexpression enhances ERK 
phosphorylation and proliferation of Pac1
In order to delineate whether urotensin II-induced signal-
ing occurs through the urotensin II receptor, cells were 
kept in reduced serum for treatment groups (Ad-GoGFP, 
Ad-urotensin II receptor, Ad-urotensin II receptor + uro-
tensin II, Ad-urotensin II receptor + urotensin II + STO609). Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 6 Urotensin II-induced cellular proliferation in a dose-dependent manner. 3H-thymidine uptake in A. Pac1 and B. PAVSMC treated with urotensin II in a dose-dependent 
manner stimulates proliferation (n = 4, *P # 0.01). C) Cell counting was used as a measure of cellular proliferation in Pac. Experiment was blinded and six independent 
experiments were conducted with triplicates (n = 18, *P # 0.05). D) A representative image of control and 100 nM urotensin II (image 20 × objective) in Pac1.
Abbreviations: Pac1, pulmonary arterial vascular smooth muscle cells; PAVSMC, primary aortic vascular smooth muscle cells; UII, urotensin II.
We overexpressed the urotensin II receptor by infecting 
Pac1 with a urotensin II receptor adenovirus (Ad-urotensin 
II) in the presence and absence of urotensin II or STO609. 
Ten percent of serum-treated cells in the presence of the 
Ad-urotensin II receptor were compared with the reduced 
serum treatment groups to determine if urotensin II or 
full serum specifically affects the urotensin II receptor 
proliferation signaling pathway. We measured downstream 
targets, such as ERK phosphorylation (Figure 9A), and cel-
lular proliferation (Figures 9B–D). Our results reveal that 
urotensin II receptor overexpression enhances urotensin 
II-induced ERK phosphorylation and cellular prolifera-
tion of Pac1.
Discussion
The results reported here demonstrate that urotensin II 
induces Ca2+/calmodulin-dependent kinase-dependent 
  proliferation of Pac1 and PAVSMC. Furthermore, our 
  present study identified that, in vascular smooth muscle cells, 
urotensin II-induced phosphorylation of several urotensin II 
receptor downstream targets can be blocked using a CaMKK 
inhibitor. These findings suggest that CaMKK inhibition may 
have therapeutic relevance by blocking cellular proliferation 
in Pac1 and PAVSMC.
The urotensin II receptor signaling pathway was initially 
thought to be activated by the single agonist, urotensin II.5 
However, recent evidence identified urotensin II-related 
peptide as an additional agonist of the urotensin II recep-
tor, similarly activating urotensin II-induced downstream 
targets.27 Both agonists have been observed to play a role in 
disease processes, although the scope of our study did not 
include urotensin II-related peptide effects on urotensin II 
receptor signaling.27,28 Hirose et al demonstrated that dur-
ing heart failure, urotensin II-related peptide   expression is Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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increased in the atrium and right ventricle of the heart.29 
Within the past decade, studies have observed the effects of 
urotensin II binding of the urotensin II receptor in various 
tissues including the brain, kidney, heart, and vessels.30 Cel-
lular proliferation in all these tissue types, except for heart, 
has shown a close correlation with increases in urotensin II 
levels.30 Previous studies involving human umbilical vein 
cells show that urotensin II induces ERK phosphoryla-
tion and cellular proliferation.20 ERK has been recognized 
as a target for several G-protein coupled   receptors, and 
its activation is correlated with proliferation.18,31 ERK 
activation is dependent on several intracellular signals, 
including an increase in intracellular Ca2+.32 Tamura et al 
has shown that urotensin II receptor signaling stimulates 
ERK phosphorylation via the classical pathways involving 
Ras and Raf in primary thoracic aortic cells.21 Conversely, 
Sauzeau et al revealed via BrdU and cell counting assays 
that urotensin II stimulates human aortic smooth muscle cell 
proliferation through RhoA and Rho kinase.33 Although our 
studies indicate that activation of cell proliferation by the 
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Figure 7 CaMKK inhibitor reduces urotensin II-induced cellular proliferation in Pac1 and PAVSMC. Proliferation studies involved serum starvation for A 24 hours and B 
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10% fetal bovine serum in media (n = 4, *P # 0.05, ++P # 0.01, +++P # 0.001, ***P # 0.001). C) Cell counting was performed as a method to measure cellular proliferation 
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A) A representative immunoblot demonstrates that urotensin II-induced phosphorylation of CaMKI is independent of extracellular Ca2+. Pac1 were treated with 
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urotensin II receptor and its Gq-coupled receptor requires 
Ca2+ activation of CaMK, it is possible that induction of 
Ras/Raf or Rho kinase pathways may also be involved. 
Schmidt et al had shown in hippocampal cells that CaMKI 
stimulates ERK phosphorylation, and conversely reduced 
ERK phosphorylation using a dominant negative CaMKI 
or pharmacologic inhibitors to CaMKI, which is consistent 
with our findings.20
Previous studies examining cellular proliferation identi-
fied the sarcoplasmic reticulum as the predominant source 
of Ca2+ release during proliferation. Dramatic changes 
in Ca2+ flux have been linked to cardiovascular disease, 
such as arteriosclerosis and renal disease.34,35 However, 
the mechanisms inducing intracellular Ca2+ flux are not 
yet well defined. Others have demonstrated that Ca2+/
ATPase and sarco/endoplasmic reticulum Ca2+-ATPase 
pumps could modulate cytoplasmic Ca2+ increases during 
proliferation.37 Recent proliferation studies have shown that 
the intracellular store involved in sarcoplasmic reticulum 
release (via Ca2+-induced Ca2+ release) may occur through 
the ryanondine receptor.36,37 We have not identified the 
source or the specific mechanism of intracellular Ca2+ 
release, although future studies will entail delineating 
which intracellular Ca2+ store is involved in the urotensin 
II-induced signaling pathway. Currently it is our belief 
that the primary mechanism of this Gq signaling-mediated 
event occurs through inositol triphosphate and modulates 
the release of Ca2+.
Although our studies indirectly identify Ca2+/calmodulin 
kinases as the target signaling kinases in the urotensin II-
urotensin II receptor pathway, future studies are needed to 
elucidate urotensin II receptor signaling mechanisms using 
a urotensin II receptor-specific antagonist. We have used an 
adenovirus to overexpress the urotensin II receptor, although 
using siRNA to the urotensin II receptor or a direct inhibitor 
will determine the involvement of Ca2+/calmodulin kinases in 
the urotensin II-induced proliferation pathways of vascular 
smooth muscle cells.
In summary, Pac1 and PAVSMC cultures exposed to 
urotensin II result in cellular proliferation, and CaMKK 
inhibitor treatment blocks cellular proliferation. Understand-
ing CaMKK’s role in urotensin II-induced proliferation may 
provide further insight into potential therapeutic targets for 
vascular smooth muscle cell proliferation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 9 Overexpression of the urotensin II receptor in the presence of urotensin II enhances ERK phosphorylation and cellular proliferation in Pac1 cells.  A) A representative 
immunoblot demonstrates that the Ad-urotensin II receptor in the presence of urotensin II, induces ERK phosphorylation in Pac1. B) A representative image of proliferating 
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Disclosure
The authors report no conflicts of interest in this work.
References
1.  Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary 
vascular remodeling in pulmonary hypertension. Prog Cardiovasc 
Dis. 2002;45(3):173–202. 
2.  Rudijanto A. The role of vascular smooth muscle cells on the pathogen-
esis of atherosclerosis. Acta Med Indones. 2007;39(2):86–93.
3.  Matsushita M, Shichiri M, Fukai N, et al. Urotensin II is an autocrine/
paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. 
Endocrinology. 2003;144(5):1825–1831. 
4.  Cohen JD. Overview of physiology, vascular biology, and mechanisms 
of hypertension. J Manag Care Pharm. 2007;13  Suppl 5:S6–S8.
5.  Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as 
a link between hypertension and coronary artery disease. Hypertens Res. 
2006;29(6):375–387.
6.  Matsusaka S, Wakabayashi I. Enhancement of   vascular smooth 
muscle cell migration by urotensin II.   Naunyn-Schmiedebergs Arch   
Pharmacol. 2006;373(5):381–386.
7.  Matsushita M, Shichiri M, Imai T, et al. Co expression of urotensin II 
and its receptor (GPR14) in human cardiovascular and renal tissues. J 
Hypertens. 2001;19(12):2185–2190.
8.  Papadopoulos P, Bousette N, Giaid A. Urotensin II and cardiovascular   
remodeling. Peptides. 2008;29(5):764–769.
9.  Hidalgo C, Nunez MT. Calcium, iron and neuronal   function.   
IUBMB Life. 2007;59(4–5):280–285. Available at : http://www3.   
interscience.wiley.com/journal/117879563/abstract?CRETRY= 
1&SRETRY=0. Accessed on Jul 15, 2010.Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
734
Iglewski and Grant
  10.  Wang YX, Ding YJ, Zhu YZ, Shi Y, Yao T, Zhu YC. Role of PKC in 
the novel synergistic action of urotensin II and angiotensin II and in 
urotensin II induced vasoconstriction. Am J Physiol Heart Circ Physiol. 
2007;292(1):H348–H359.
  11.  Rothman A,  Kulik TJ, Taubman  MB,  Berk  BC,  Smith  CW, 
  Nidel-Ginard B. Development and characterization of a cloned rat pulmo-
nary arterial smooth muscle cell line that maintains differentiated proper-
ties through multiple subcultures. Circulation. 1992;86(6):1977–1986.
 12.  Cobb MH, Hepler JE, Cheng M, Robbins D. The mitogen activated protein 
kinases, ERK1 and ERK2. Semin Cancer Biol. 1994;5(4):261–268.
  13.  Tokumitsu H, Takahashi N, Eto K, Yano S, Soderling TR, Muramatsu M. 
Substrate recognition by Ca2+/Calmodulin dependent protein 
kinase kinase. Role of the arg pro rich insert domain. J Biol Chem. 
1999;274(22):15803–15810.
  14.  McKinsey TA. Derepression of pathological cardiac genes by mem-
bers of the CaM kinase superfamily. Cardiovasc Res. 2007;73(4): 
667–677.
  15.  Rozengurt E. Mitogenic signaling pathways induced by G protein-
coupled receptors. J Cell Physiol. 2007;213(3):589–602.
  16.  Shi L, Ding W, Li D, et al. Proliferation and anti apoptotic effects 
of human urotensin II on human endothelial cells. Atherosclerosis. 
2006;188(2):260–264.
  17.  Brose N, Rosenmund C. Move over protein kinase C, you’ve got 
company: Alternative cellular effectors of diacylglycerol and phorbol 
esters. J Cell Sci. 2002;115(Pt 23):4399–4411.
  18.  Raiesdana A, Loscalzo J. Pulmonary arterial hypertension. Ann Med. 
2006;38(2):95–110.
  19.  Nakagawa Y, Kuwahara K, Harada M, et al. Class II HDACs mediate 
CaMK dependent signaling to NRSF in ventricular myocytes. J Mol 
Cell Cardiol. 2006;41(6):1010–1022.
  20.  Schmitt JM, Guire ES, Saneyoshi T, Soderling TR. Calmodulin 
dependent kinase kinase/calmodulin kinase I activity gates extracel-
lular regulated kinase dependent long term potentiation. J Neurosci. 
2005;25(5):1281–1290.
  21.  Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. 
Urotensin II induced activation of extracellular signal regulated kinase 
in cultured vascular smooth muscle cells: Involvement of cell adhesion 
mediated integrin signaling. Life Sci. 2003;72(9):1049–1060.
 22.  Guibert C, Marthan R, Savineau JP. Modulation of ion channels in pulmo-
nary arterial hypertension. Curr Pharm Res. 2007;13(24):2443–2455.
  23.  Travo P, Barrett G, Burnstock G. Differences in proliferation of primary 
cultures of vascular smooth muscle cells taken from male and female 
rats. Blood Vessels. 1980;17(2):110–116.
  24.  Dibas A, Prasanna G, Yorio T. Localization of endothelin converting 
enzyme in bovine optic nerve and retina. J Ocul Pharmacol Ther. 
2005;21(4):288–297.
  25.  Onan D, Pipolo L, Yang E, Hannah RD, Thomas WG. Urotensin II 
promotes hypertrophy of cardiac myocytes via mitogen activated protein 
kinases. Mol Endocrinol. 2004;18(9):2344–2354. 
  26.  Ames RS, Sarau HM, Chambers JK, et al. Human urotensin II is a potent 
vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 
1999;401(6750):282–286.
  27.  Jarry M, Diallo M, Lecointre C, et al. The vasoactive peptides urotensin 
II and urotensin II related peptide regulate astrocyte activity through 
common and distinct mechanisms: Involvement in cell proliferation. 
Biochem J. 2010;428(1):113–124.
  28.  Kristof AS, You Z, Hans YS, Giaid A. Protein expression of urotensin 
II, urotensin related peptide, and their receptor in the lungs of patients 
with lymphangioleiomyomatosis. Peptides. 2010 May 28. [Epub ahead 
of print].
  29.  Hirose T, Takahashi K, Mori N, et al. Increased expression of urotensin 
II, urotensin II related peptide and urotensin II receptor mRNAs in the 
cardiovascular organs of hypertensive rats: Comparison with   endothelin 1. 
Peptides. 2009;30(6):1124–1129.
  30.  Yoshimoto T, Matsushita M,  Hirata Y. Role of urotensin II in 
peripheral tissue as an autocrine/paracrine growth factor. Peptides. 
2004;25(10):1775–1781.
  31.  Soderling TR. The Ca calmodulin dependent protein kinase cascade. 
Trends Biochem Sci. 1999;24(6):232–236.
  32.  Harrison BC, Kim MS, van Rooij E, et al. Regulation of cardiac stress sig-
naling by protein kinase d1. Mol Cell Biol. 2006;26(10):3875–3888.
  33.  Sauzeau V , Le Mellionec E, Bertiglio J, Scalbert E, Pacaud P, Loirand 
G. Human urotensin II induced contraction and arterial smooth muscle 
cell proliferation are mediated by RhoA and Rho kinase. Circ Res. 
2001;88(11):1102–1104.
  34.  Inoue R, Hai L, Honda A. Pathophysiological implications of transient 
receptor potential channels in vascular function. Curr Opin Nephrol 
Hypertens. 2008;17(2):193–198.
  35.  Mene P. Transient receptor potential channels in the kidney: Calcium 
signaling, transport and beyond. J Nephrol. 2006;19(1):21–29.
  36.  Berra Romani R, Raqueeb A, Avelino-Cruz JE, et al. Ca2+ signaling 
in injured in situ endothelium of rat aorta. Cell Calcium. 2008;44(3): 
298–309.
  37.  Berra Romani R, Mazzocco-Spezzia A, Pulina MV , Golovina VA. Ca2+ 
handling is altered when arterial myocytes progress from a contractile 
to a proliferative phenotype in culture. Am J Physiol Cell Physiol. 
2008;295(3):C779–C790.